Donald B Matthews

6417212, Jul 9, 2002

Aug 23, 2000

09/644457

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Eli Lilly Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

C07D26336

514374, 548235

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

6610696, Aug 26, 2003

Apr 11, 2002

10/121373

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Eli Lilly and Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 3142

514256, 548236, 544333, 546198, 514374, 514338

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

6825222, Nov 30, 2004

May 7, 2003

10/434425

Dawn A. Brooks - Indianapolis IN
Christopher J. Rito - Martinsville IN
Anthony J. Shuker - Atlanta GA
Samuel J. Dominianni - Indianapolis IN
Alan M. Warshawsky - Carmel IN
Lynn S. Gossett - Indianapolis IN
Donald P. Matthews - Indianapolis IN
David A. Hay - Indianapolis IN
Robert J. Ardecky - Encinitas CA
Pierre-Yves Michellys - San Diego CA
John S. Tyhonas - San Diego CA

Eli Lilly and Company - Indianapolis IN
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 31425

514365, 548204

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO ; R is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R is H, a C1-C4 alkyl, or an aminoalkyl.

7282501, Oct 16, 2007

May 24, 2002

10/477405

Lynn Stacy Gossett - Indianapolis IN, US
Jonathan Edward Green - Greencastle IN, US
James Robert Henry - Indianapolis IN, US
Winton Dennis Jones - Carmel IN, US
Donald Paul Matthews - Indianapolis IN, US
Quanrong Shen - Fishers IN, US
Daryl Lynn Smith - Fishers IN, US
Jennifer Ann Vance - San Jose CA, US
Alan M. Warshawsky - Carmel IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/535
A61K 31/42
A61K 31/445
A61K 31/4965
C07D 263/34
C07D 275/04
C07D 413/10

5142368, 514374, 514326, 514256, 51425505, 514340, 548236, 548209, 544137, 544333, 544405, 5462714

The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

7655641, Feb 2, 2010

Feb 10, 2004

10/542579

Scott Eugene Conner - Indianapolis IN, US
Lynn Stacy Gossett - Indianapolis IN, US
Jonathan Edward Green - Avon IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Donald Paul Matthews - Indianapolis IN, US
Daniel Ray Mayhugh - Carmel IN, US
Daryl Lynn Smith - Fishers IN, US
Jennifer Ann Vance - San Jose CA, US
Xiaodong Wang - Carmel IN, US
Alan M Warshawsky - Carmel IN, US
Yanping Xu - Fishers IN, US
Guoxin Zhu - Noblesville IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/66
A61K 31/38
C07D 409/12
C07D 209/04

514141, 514443, 548467, 549 51, 549 52, 549 54, 549 55

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

7803814, Sep 28, 2010

Dec 8, 2004

10/576761

Konstantinos Gavardinas - Monrovia IN, US
Jonathan Edward Green - Avon IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
Donald Paul Matthews - Indianapolis IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/445
C07D 401/14

514320, 546196

The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

7935722, May 3, 2011

Jun 21, 2006

11/917398

Kevin Robert Fales - Avon IN, US
Jonathan Edward Green - Avon IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
Donald Paul Matthews - Indianapolis IN, US
David Andrew Neel - Zionsville IN, US
Edward C R Smith - Fishers IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/403
A61K 31/4439
A61K 31/427
C07D 209/82

514411, 514410, 540 1, 548400, 548416, 548418, 548427, 548439

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).

7968587, Jun 28, 2011

Nov 6, 2007

12/447693

Konstantinos Gavardinas - Monrovia IN, US
Jonathan Edward Green - Avon IN, US
Prabhakar Kondaji Jadhav - Zionsville IN, US
Donald Paul Matthews - Indianapolis IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/403
C07D 209/60

514411, 548427

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.